The bottleneck in AI-powered drug development isn't computing power or model sophistication anymore; it's the quality and organization of biological data itself. As artificial intelligence models mature and computing costs plummet, the companies that will dominate the next generation of drug discovery are those investing in purpose-built data infrastructure designed specifically for biology, according to analysis from Bessemer Venture Partners .

Much of the data powering today's AI biology models was painstakingly assembled over decades by publicly-funded science. The Protein Data Bank contains over 200,000 protein structures determined through techniques like X-ray crystallography and nuclear magnetic resonance spectroscopy. The Human Genome Project mapped human genes and DNA through sequencing efforts across global research institutions. ChEMBL's bioactivity database accumulated millions of small molecule records through years of manual patent and literature extraction . These foundational datasets have proven remarkably valuable; structural data from the Protein Data Bank contributed to the development of 100% of the protein-targeted small-molecule cancer drugs approved by the FDA between 2019 and 2023 .

But here's the problem: this approach doesn't scale for the AI era. Public databases are static, often incomplete, and rarely organized in ways that modern machine learning models need. Companies building the next wave of AI-driven biotechs can't rely on yesterday's data infrastructure.

What Makes Biology-Native Data Infrastructure Different?

Biology-native data infrastructure isn't just about collecting more data; it's about fundamentally rethinking how biological information is organized, curated, and fed into AI systems. According to Bessemer Venture Partners, three core principles define this new approach :

• Multi-Modal Datasets: Curating scalable datasets that combine multiple types of biological measurements, informed by the specific challenges associated with a drug's mechanism of action rather than generic, one-size-fits-all databases.
• Agentic AI Workflows: Incorporating the newest agentic AI frameworks (systems that can autonomously plan and execute tasks) across entire research and development workflows, allowing AI to orchestrate complex experiments without constant human intervention.
• Lab Automation: Adopting laboratory automation to power rapid, closed experimental feedback loops where AI predictions are immediately tested in the wet lab and results feed back into the model.

The third principle is particularly crucial. Despite dramatic advances in structure prediction and molecular modeling, many computational predictions, such as binding affinity estimates, still need validation in the wet lab before any downstream development decision can be made with confidence. Beyond that, real-world efficacy in living organisms remains essentially unpredictable from first principles, with late-stage drug failures driven disproportionately by pharmacokinetic and toxicity properties that computational models failed to flag .

Why Can't AI Models Just Learn From Existing Data?

The fundamental issue is that experimental results are the ultimate source of biological ground truth. AI models trained only on historical data become anchored to the limitations and biases of that data. Without continuous feedback from actual laboratory experiments, models drift away from accuracy in real-world applications .

This creates a virtuous cycle for companies that invest in biology-native infrastructure: they generate novel, multi-modal biological measurements that broaden understanding of disease, build datasets with the scale and consistency needed to train generalizable models, and use lab automation to rapidly test and refine those models. Each iteration makes the next iteration faster and more accurate .

How to Build Adaptable AI Infrastructure for Drug Development

Companies entering the AI drug discovery space face a critical strategic choice: build infrastructure that's locked into today's best tools, or build systems flexible enough to adopt tomorrow's breakthroughs. Here's what forward-thinking biotech companies are doing :

• Modular Architecture: Design systems that autonomously leverage and orchestrate the best tools for particular tasks, whether that's literature review, bioinformatics pipelines, or molecular modeling, rather than betting everything on a single AI platform or stack.
• Rapid Tool Integration: Build infrastructure from day one with the ability to test, implement, and leverage the newest AI tools as they emerge, ensuring the company isn't anchored to any single technology that may become obsolete.
• Closed-Loop Experimentation: Establish systems where computational predictions automatically trigger laboratory experiments, results are captured in standardized formats, and findings immediately retrain the AI models, creating continuous improvement cycles.

The economic incentive is compelling. While the cost of bringing a drug to market has increased over the past few decades, the cost of computing has decreased exponentially since the 1950s, consistent with Moore's Law. Tasks along the drug development continuum that are computationally expensive today will be dramatically cheaper within a few years . Companies that build adaptable infrastructure will find themselves with an increasingly substantial structural advantage over those that view AI as a fixed investment.

What Does This Mean for the Future of Biotech?

The companies that will define the next generation of life science innovation are those building large biology-native datasets, AI-centric development stacks, and lab automation platforms that power rapid closed-loop experimentation . This isn't just about being faster than competitors; it's about creating a sustainable competitive moat that becomes harder to replicate as proprietary datasets and experimental feedback loops accumulate.

The shift represents a fundamental change in how biotech companies think about their technology infrastructure. Rather than treating AI as a tool layered on top of existing processes, leading companies are rebuilding their entire R&D infrastructure around AI from the ground up, with biology-native data at the foundation.